FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979678340> ?p ?o ?g. }

• W2979678340 endingPage "104" @default.
• W2979678340 startingPage "104" @default.
• W2979678340 abstract "Abstract Introduction DLBCL is the most common lymphoid neoplasm in adults (Swerdlow 2016). While durable CRs are achieved in approximately 70% of patients (pts) with frontline RCHOP therapy (Pfreundschuh 2008), pts with high-risk features often experience disease resistance or relapse. In Part 1 of an ongoing study, pts with high-intermediate or high risk DLBCL by international prognostic index (IPI) scores, regardless of CD30 expression by IHC, were treated with 1.2 or 1.8 mg/kg brentuximab vedotin (BV) combined with RCHOP. After 3 of the first 10 pts treated at 1.8 mg/kg BV+RCHOP developed Grade 3 peripheral neuropathy (per Standardized MedDRA Query [SMQ]), all pts enrolled subsequently received treatment with 1.2 mg/kg BV+RCHOP. Following completion of enrollment in Part 1, the protocol was amended to enroll a non-randomized portion of the study (Part 2) evaluating the safety and efficacy of 1.8 mg/kg BV+RCHP (Yasenchak 2015), followed by an open-label, randomized portion comparing BV+RCHP to RCHOP (Part 3). Initial results from Part 2 and updated results from Part 1 are reported here. Methods For Part 2 of the study, pts with CD30-expressing high-intermediate and high-risk DLBCL were treated with up to 6 cycles of 1.8 mg/kg BV+RCHP (NCT01925612). Key inclusion criteria were CD30 expression by IHC performed by a local pathology lab and standard IPI scores of 3-5 or age-adjusted IPI (aaIPI) scores of 2-3 (high-intermediate/high risk). CD30 expression was confirmed by a central pathology lab, although CD30 expression by local pathology lab was required for eligibility. Disease response was evaluated with PET/CT per Cheson 2007. Results At the time of analysis for this ongoing study, 11 pts in Part 2 were treated with BV+RCHP (7 male, 4 female; 22-78 yrs). Of these pts, 9 had high-intermediate risk (IPI 3, aaIPI 2) and 2 had high risk disease (IPI 4-5, aaIPI 3), 6 had Stage IV disease, and 6 had an ECOG score of 2. At the end of treatment, the overall response rate was 91% (9 CR, 1 PR); 1 pt had PD after Cycle 4. The most frequent (>20%) treatment-emergent adverse events (AEs) were alopecia and nausea (73% each); fatigue (64%); constipation and peripheral sensory neuropathy (55% each); neutropenia and throat irritation (36% each); and chills, diarrhea, headache, and stomatitis (27% each). Grade 3 or 4 AEs occurred in 8 pts and 5 pts had serious AEs, which included febrile neutropenia, bacteremia, nausea, pneumocystis jiroveci pneumonia, pulmonary embolism, and vomiting. Peripheral sensory neuropathy occurred in 6 pts and all were Grade 1 or 2 events; no peripheral motor neuropathy AEs were reported. No AEs were fatal or led to discontinuation. One pt discontinued treatment after Cycle 4 due to disease progression. For the first 51 pts in Part 1, the progression-free survival (PFS) at 18 months for pts with CD30 expression (25 pts) or without detectable CD30 expression (24 pts) by IHC was 79% (95% CI: 57%, 91%) versus 58% (95% CI: 36%, 75%), respectively. Overall survival for pts was 92% (95% CI: 71%, 98%) versus 71% (95% CI: 48%, 85%), respectively. Ten pts had pre-existing peripheral neuropathy (per SMQ) at study entry. Treatment-emergent peripheral neuropathy (per SMQ) was observed in 75% of pts (38/51) who received BV+RCHOP; 55% of these pts (21/38) had resolution of all or some peripheral neuropathy events. Conclusions 1.8 mg/kg BV+RCHP is active as frontline treatment in CD30-expressing, high-intermediate/high risk DLBCL. When combined with RCHP, 1.8 mg/kg BV appears to be well-tolerated. The PFS and OS for pts with CD30-expression who received BV+RCHOP appear promising. The study is currently ongoing in pts with CD30-expressing high-intermediate/high risk DLBCL to assess the safety and activity of 1.8 mg/kg BV+RCHP versus standard RCHOP. Disclosures Halwani: Bristol Myers-Squibb: Research Funding; Kyowa Hakko Kirin: Research Funding; Takeda: Research Funding; Genentech: Research Funding; AbbVie: Consultancy, Other: Travel Expenses, Research Funding; Seattle Genetics: Consultancy, Research Funding; Immune Design: Research Funding; Miragen: Research Funding; Pharmacyclics: Consultancy; Amgen: Research Funding. Yasenchak:Seattle Genetics: Research Funding. Farber:Seattle Genetics: Research Funding. Burke:Pfizer: Consultancy; Janssen: Consultancy; Incyte: Consultancy; TG Therapeutics: Other: Travel Expenses; Millenium: Consultancy. Fayad:Seattle Genetics: Consultancy, Research Funding. Holkova:Seattle Genetics: Research Funding. Knapp:Insys Therapeutics, Inc.: Consultancy, Other: Travel, Accommodations, Expenses; Pharmacyclics, LLC, an AbbVie Company: Consultancy, Other: Travel, Accommodations, Expenses, Research Funding. Kolibaba:Gilead: Consultancy, Research Funding; Celgene: Research Funding; TG Therapeutics: Research Funding; Takeda Pharmaceuticals International Co.: Research Funding; Seattle Genetics: Research Funding; Pharmacyclics: Research Funding; janssen: Research Funding; GSK: Research Funding; Genentech: Research Funding; Acerta: Research Funding. Patel-Donnelly:Seattle Genetics: Research Funding. Yimer:Ariad Pharmaceuticals: Consultancy; Biotheranostics: Consultancy; Bluebird Bio: Equity Ownership; Kite Pharma: Equity Ownership; Clovis Oncology: Equity Ownership; Juno Therpeutics: Equity Ownership; Seattle Genetics: Research Funding. Smith:Celgene: Consultancy, Speakers Bureau; Seattle Genetics: Research Funding. Levy:Janssen: Speakers Bureau; Amgen: Speakers Bureau; Takeda Pharmaceuticals International Co.: Speakers Bureau; Seattle Genetics: Research Funding; Actinium Pharmaceuticals, Inc.: Research Funding. Seetharam:Seattle Genetics: Research Funding. Belada:Seattle Genetics: Research Funding. Brooks:Seattle Genetics: Research Funding. Kingsley:Gilead: Equity Ownership; Pharmacyclics LLC, an AbbVie Company: Equity Ownership. Wagner-Johnston:Seattle Genetics: Research Funding. Ruffner:Forma Therapeutics: Consultancy; Sydnax: Consultancy; Seattle Genetics: Employment, Equity Ownership; Array Biopharma: Employment; Medivation: Employment. Bartlett:Gilead: Consultancy." @default.
• W2979678340 created "2019-10-18" @default.
• W2979678340 creator A5009060912 @default.
• W2979678340 creator A5017045452 @default.
• W2979678340 creator A5024431512 @default.
• W2979678340 creator A5028677309 @default.
• W2979678340 creator A5033508968 @default.
• W2979678340 creator A5036543091 @default.
• W2979678340 creator A5036866696 @default.
• W2979678340 creator A5042998970 @default.
• W2979678340 creator A5048992211 @default.
• W2979678340 creator A5050261367 @default.
• W2979678340 creator A5053711811 @default.
• W2979678340 creator A5059729547 @default.
• W2979678340 creator A5060314041 @default.
• W2979678340 creator A5061916244 @default.
• W2979678340 creator A5062430369 @default.
• W2979678340 creator A5064830159 @default.
• W2979678340 creator A5071289346 @default.
• W2979678340 creator A5072273907 @default.
• W2979678340 creator A5078397650 @default.
• W2979678340 creator A5078594503 @default.
• W2979678340 creator A5082326885 @default.
• W2979678340 creator A5086403929 @default.
• W2979678340 creator A5090935889 @default.
• W2979678340 date "2016-12-02" @default.
• W2979678340 modified "2023-10-01" @default.
• W2979678340 title "Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL)" @default.
• W2979678340 doi "https://doi.org/10.1182/blood.v128.22.104.104" @default.
• W2979678340 hasPublicationYear "2016" @default.
• W2979678340 type Work @default.
• W2979678340 sameAs 2979678340 @default.
• W2979678340 citedByCount "11" @default.
• W2979678340 countsByYear W29796783402017 @default.
• W2979678340 countsByYear W29796783402018 @default.
• W2979678340 countsByYear W29796783402019 @default.
• W2979678340 countsByYear W29796783402021 @default.
• W2979678340 countsByYear W29796783402022 @default.
• W2979678340 countsByYear W29796783402023 @default.
• W2979678340 crossrefType "journal-article" @default.
• W2979678340 hasAuthorship W2979678340A5009060912 @default.
• W2979678340 hasAuthorship W2979678340A5017045452 @default.
• W2979678340 hasAuthorship W2979678340A5024431512 @default.
• W2979678340 hasAuthorship W2979678340A5028677309 @default.
• W2979678340 hasAuthorship W2979678340A5033508968 @default.
• W2979678340 hasAuthorship W2979678340A5036543091 @default.
• W2979678340 hasAuthorship W2979678340A5036866696 @default.
• W2979678340 hasAuthorship W2979678340A5042998970 @default.
• W2979678340 hasAuthorship W2979678340A5048992211 @default.
• W2979678340 hasAuthorship W2979678340A5050261367 @default.
• W2979678340 hasAuthorship W2979678340A5053711811 @default.
• W2979678340 hasAuthorship W2979678340A5059729547 @default.
• W2979678340 hasAuthorship W2979678340A5060314041 @default.
• W2979678340 hasAuthorship W2979678340A5061916244 @default.
• W2979678340 hasAuthorship W2979678340A5062430369 @default.
• W2979678340 hasAuthorship W2979678340A5064830159 @default.
• W2979678340 hasAuthorship W2979678340A5071289346 @default.
• W2979678340 hasAuthorship W2979678340A5072273907 @default.
• W2979678340 hasAuthorship W2979678340A5078397650 @default.
• W2979678340 hasAuthorship W2979678340A5078594503 @default.
• W2979678340 hasAuthorship W2979678340A5082326885 @default.
• W2979678340 hasAuthorship W2979678340A5086403929 @default.
• W2979678340 hasAuthorship W2979678340A5090935889 @default.
• W2979678340 hasBestOaLocation W29796783401 @default.
• W2979678340 hasConcept C126322002 @default.
• W2979678340 hasConcept C141071460 @default.
• W2979678340 hasConcept C143998085 @default.
• W2979678340 hasConcept C2778191690 @default.
• W2979678340 hasConcept C2778476033 @default.
• W2979678340 hasConcept C2778559949 @default.
• W2979678340 hasConcept C2779338263 @default.
• W2979678340 hasConcept C70905583 @default.
• W2979678340 hasConcept C71924100 @default.
• W2979678340 hasConceptScore W2979678340C126322002 @default.
• W2979678340 hasConceptScore W2979678340C141071460 @default.
• W2979678340 hasConceptScore W2979678340C143998085 @default.
• W2979678340 hasConceptScore W2979678340C2778191690 @default.
• W2979678340 hasConceptScore W2979678340C2778476033 @default.
• W2979678340 hasConceptScore W2979678340C2778559949 @default.
• W2979678340 hasConceptScore W2979678340C2779338263 @default.
• W2979678340 hasConceptScore W2979678340C70905583 @default.
• W2979678340 hasConceptScore W2979678340C71924100 @default.
• W2979678340 hasIssue "22" @default.
• W2979678340 hasLocation W29796783401 @default.
• W2979678340 hasOpenAccess W2979678340 @default.
• W2979678340 hasPrimaryLocation W29796783401 @default.
• W2979678340 hasRelatedWork W2075864830 @default.
• W2979678340 hasRelatedWork W2091104789 @default.
• W2979678340 hasRelatedWork W2112285079 @default.
• W2979678340 hasRelatedWork W2115179216 @default.
• W2979678340 hasRelatedWork W2116688508 @default.
• W2979678340 hasRelatedWork W2346728804 @default.
• W2979678340 hasRelatedWork W2586114043 @default.
• W2979678340 hasRelatedWork W2981634038 @default.
• W2979678340 hasRelatedWork W3023665323 @default.
• W2979678340 hasRelatedWork W4232815876 @default.
• W2979678340 hasVolume "128" @default.
• W2979678340 isParatext "false" @default.

• next